Medical papers.

Resources : Support  Glossary  Education  FAQs  Medical papers  Other good reads
Asthma.
Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007: National Asthma Education and Prevention Program.[2007]   More
Persistent airflow obstruction in asthma of patients with Churg Strauss syndrome and long-term follow-up: Cottin et al. [2009]   More
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma: Chung et al.[2014]   More

Biomarkers and Genetics.
12-HETE.
12-hydroxy-eicosatetraenoic acid (12-HETE): a biomarker of Churg Strauss syndrome: Szczeklik et al. [2012]   More [Restricted access]

ANCA.
Churg Strauss Syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists: Keogh, Specks. [2003]   More [Restricted access]
Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in Churg Strauss Syndrome: Sinico et al.[2005]   More
Antineutrophil cytoplasmic antibodies and the Churg Strauss syndrome: Sablé-Fourtassou et al. [2005]   More [Restricted access]
Antineutrophil cytoplasm autoantibodies: usefulness in rheumatology: Flores-Suarez. [2012]   More
Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg Strauss syndrome: Healy et al.[2013]   More
Diagnosing ANCA-associated vasculitis in ANCA positive patients: Houben et al.[2016]   More

B Cells.
B Cells in Autoimmune Diseases: Christiane S. Hampe [2012]  More

CCL17.
CCL17/thymus and activation related chemokine in Churg Strauss syndrome: Dallos et al. [2010]   More

Eosinophils.
Eosinophils in vasculitis: characteristics and roles in pathogenesis.: Khoury et al.[2014]   More

Eotaxin.
Eotaxin-3 is involved in Churg Strauss syndrome a serum marker closely correlating with disease activity: Polzer et al. [2007]   More
Eotaxin-3 in Churg Strauss syndrome: a clinical and immunogenetic study: Zwerina et al. [2011]   More

General.
Serum eosinophil cationic protein: a marker of disease activity in Churg Strauss syndrome: Guilpain et al.[2007]   More [Restricted access]
Expression of NKG2D and CD107 in CD8(+) effector memory lymphocytes in Churg Strauss syndrome: Boita et al. [2012]   More [Restricted access]
Increased production of IL-5 and dominant Th2-type response in airways of Churg Strauss syndrome patients: Jakiela et al. [2012]   More
Serum biomarkers are similar in Churg Strauss syndrome and hypereosinophilic syndrome: Khoury et al.[2012]   More
Cutting edge issues in the Churg Strauss syndrome: Szczeklik, Jakiela, Adamek, Musial. [2013]   More [Restricted access]
Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in EGPA: Grayson et al. [2014]   More
Biomarkers in Vasculitis: Monach [2014]   More
Serum Biomarkers in Patients with Relapsing EGPA: Dejaco et al [2015]  More

HLA.
HLA-DRB4 as a genetic risk factor for Churg Strauss syndrome: Vaglio et al. [2007]   More
The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action: Gough, Simmonds. [2007]   More

IgG4.
IgG4 immune response in Churg Strauss syndrome: Vaglio et al. [2012]   More [Restricted access]

Interleukin.
Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg Strauss Syndrome: Terrier et al.[2010]   More
Anti-IL5 therapy for asthma and beyond: Manali Mukherjee, Roma Sehmi, Parameswaran Nair [2014]  More
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs: Varricchi et al.[2016]   More


Cardiology.
Cardiac Involvement in Churg Strauss Syndrome: Dennert et al [2010]  More
Cardiac involvement in Churg Strauss syndrome: impact of endomyocarditis: Neumann et al. [2009]   More [Restricted access]
Cardiac involvement in EGPA: Szczeklik, Miszalski-Jamka [2013]   More
Churg Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients: Marmursztejn et al. [2012]   More
Comprehensive evaluation of cardiac involvement in EGPA with cardiac magnetic resonance :Cereda et al.[2016]   More [Restricted access]
Coronary Arteries Involvement in Churg Strauss Syndrome Simulating an Acute Coronary Syndrome: An Emblematic Case and Literature Review: Bucchero et al [2015]   More
Heart transplantation in patients with EGPA: Groh et al.[2014]   More [Restricted access]
Impact of cardiac magnetic resonance imaging for assessment of Churg Strauss syndrome: A cross-sectional study in 20 patients: Marmursztejn et al.[2009]   More
Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: EGPA and GPA: Hazebroek et al.[2015]   More [Restricted access+]
The significance of cardiac magnetic resonance imaging in detection and monitoring of the treatment efficacy of heart involvement in EGPA patients: Fijolek et al.[2016]   More

Classification.
The subject of classification and related references is covered in the Prologue section.

Clinical trials.
EGPA: Clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. : Comarmond et al. [2013]   More
Long term outcomes of 118 patients with EGPA enrolled in two prospective trials : Samson et al. [2013]   More [Restricted access]
Treatment of systemic necrotizing vasculitides in patients >65 years old: results of the multicenterrandomized CORTAGE trial :[2013]   Pagnoux et al. More

Demography.
Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study : Sada et al.[2014]   More
Churg Strauss Syndrome: retrospective study in Burgundian population in France in past 10 years. :Vinit et al.[2011]   More [Restricted access]
Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg Strauss syndrome within a defined population in southern Sweden :Mohammad et al.[2007]   More
Primary vasculitis in a Norwegian community hospital: A retrospective study. :Haugeberg et al.[1998]   More [Restricted access]
Stable incidence of systemic vasculitides in Schleswig-Holstein, Germany. :Herlyn et al.[2008]   More
The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern Turkey. :Pamuk et al.[2016]   More [Restricted access]

Dermatology.
Neutrophilic Dermatoses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A French Multicenter Study of 17 Cases and Literature Review.: de Boysson et al.[2016]   More [Restricted access]

Diagnosis.
Diagnosing ANCA-associated vasculitis in ANCA positive patients: Houben et al.[2016]   More
Improved Differentiation Between Churg Strauss Syndrome and Wegener's Granulomatosis by an Artificial Neural Network :  Schmitt, Linder, Reinhold-Keller, Gross [2001]  More
Recent Advances in the Diagnosis of Churg Strauss Syndrome : Andrew Churg. [2001]  More

Environment.
Are environmental factors important in primary systemic vasculitis? A case-control study. Lane et al. : [2003]   More
The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. Gomez-Puerta et al. [2013]:   More
Churg Strauss Syndrome: Singulair or Silicone (or both?) David et al. : [2016]   More

Future research.
Vasculitis Foundation research projects.  More
Vasculitis Research Studies. Rare dieases network   More
Vasculitis UK research projects.  More
Orphanet portal for rare diseases and orphan drugs. More
Clinicaltrials.gov results of clinical studies conducted around the world.  More
Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial: Walsh et al.[2013]   More

Gastroenterology.
Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg Strauss syndrome, or rheumatoid arthritis-associated vasculitis.Pagnoux et al.[2005]   More [Restricted access]
Successful Use of Plasma Exchange in the Treatment of Corticosteroid-Refractory EGPA Associated with Gastrointestinal Manifestations: Tsujimoto et al.[2016]   More

Haematology.
Thrombosis in vasculitis: from pathogenesis to treatment : Emmi et al [2015]   More

Immunology.
Neural circuitry and immunity. : Pavlov, Tracey [2015]   More
The vagus nerve and the inflammatory reflex linking immunity and metabolism. :Pavlov, Tracey [2012]   More

Infection.
Churg Strauss Syndrome and Active Chronic Hepatitis B Virus Infection: Coincidence or Association? Domiciano et al. : [2010]   More

Management.
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.:Jayne et al.[2003]   More
A vasculitis centre based management strategy leads to improved outcome in EGPA: monocentric experiences in 150 patients : Moosig et al. [2013]   More [Restricted access]
BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis :  Ntatsaki et al. [2013]  More
Effect of delayed diagnosis on disease course and management of Churg Strauss syndrome: a retrospective study. : Sokolowska et al. [2013]   More [Restricted access]
EGPA Consensus Task Force recommendations for evaluation and management : Groh et al [2015]  More
EGPA: Early diagnosis is better : Christian Pagnoux, MD MPH MSc [2013]  More
EULAR recommendations for the management of primary small and medium vessel vasculitis.: Mukhtyar et al.[2008]   More [Restricted access]
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis: Yates et al.[2016]   More
Linking classification and therapeutic management of vasculitides: Baldwin et al.[2015]   More
Recent advances in understanding and treating vasculitis : Koster et al. [2016]   More
Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis a systematic review: Bosch et al. [2007]   More
Treatment of Churg Strauss Syndrome without poor prognosis factors : Ribi et al. [2008]  More

Medication and other therapies.
Alternative therapies.
Herbal treatment in asthma and COPD - current evidence : Clarke et al.[2015]   More

Azathioprine.
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies: Jayne et al.[2003]   More
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis: Pagnoux et al. [2008]   More
Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. A Randomized Controlled Trial.:Hiemstra et al.[2010]   More

Corticosteroids.
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Hoes et al.[2007]   More
Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Van der Goes et al.[2009]   More

Co-trimoxazole.
Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement:Zycinska et al.[2009]   More

Cyclophosphamide.
Churg Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. : Cohen et al. [2007]   More [Restricted access]
Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg Strauss syndrome patients with factors predicting poor prognosis. :Guillevin et al.[1995]   More [Restricted access]
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. :Harper et al.[2012]   More [Restricted access]
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis: De Groot et al. [2005]   More [Restricted access]
The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. :de Groot et al.[2001]   More

Immunoglobulin.
Efficacy of high-dose intravenous immunoglobulin therapy for peripheral neuropathy in the remission stage of EGPA. : Matsuda et al.[2013]   More
High-dose intravenous immunoglobulin therapy for EGPA : Tsurikisawa et al. [2014]   More
Intravenous immunoglobulin for chronic residual peripheral neuropathy in EGPA a multicenter, double-blind trial: Koke et al.[2015]   More
Long term effectiveness of intravenous immunoglobulin in Churg Strauss syndrome : Danieli et al. [2004]   More
Treatment of Churg Strauss syndrome with high dose intravenous immunoglobulin.:Tsurikisawa et al.[2004]   More [Restricted access]

Interferons.
A phase II study of interferon-alpha for the treatment of refractory Churg Strauss syndrome : Metzler et al. [2008]   More
Interferon-alpha for maintenance of remission in Churg Strauss syndrome: a long-term observational study.:Metzler et al.[2010]   More
Interferon- α for Induction and Maintenance of Remission in EGPA: A Single-center Retrospective Observational Cohort Study.:Seeliger et al.[2017]   More [Restricted access]

Mepolizumab.
Mepolizumab as a steroid-sparing treatment option in patients with Churg Strauss syndrome. : Kim et al. [2010]   More [Restricted access]
Extended follow-up after stopping mepolizumab in relapsing/refractory Churg Strauss syndrome. :Herrmann et al.[2012]   More [Restricted access]
Mepolizumab in eosinophilic disorders : Abonia, Putnam. [2012]   More
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma: Ortega et al.[2014]   More
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma: Bel et al.[2014]   More
Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential: Menzella et al.[2016]   More
Mepolizumab or Placebo for EGPA.: Wechsler et al.[2017]   More

Methotrexate.
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis: Pagnoux et al. [2008]   More
Churg Strauss syndrome. Successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment : Metzler et al. [2004]   More
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis: De Groot et al. [2005]   More [Restricted access]

Montelukast.
Churg Strauss syndrome in patients receiving montelukast as treatment for asthma: Wechsler et al.[2000]   More
Neuropathy in EGPA : a comparison study of 24 cases with or without prior leukotriene antagonist exposure.: Giusti Del Giardino et al.[2014]   More

Mycophenolate.
Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. A Randomized Controlled Trial.:Hiemstra et al.[2010]   More

Omalizumab.
Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing EGPA (Churg Strauss): Data from 17 patients.: long-term follow-up. :Jachiet et al.[2016]   More [Restricted access]
Churg Strauss syndrome in patients treated with omalizumab.: Wechsler et al.[2009]   More [Restricted access]

Rituximab.
Rituximab for the treatment of Churg Strauss syndrome with renal involvement : Cartin-Ceba et al. [2011]   More
Rituximab in the treatment of refractory or relapsing EGPA : Thiel et al. [2013]   More
Rituximab for the treatment of EGPA : Mohammad et al. [2014]   More [Restricted access]
Rituximab in the treatment of EGPA : Munoz et al. [2014]   More [Restricted access]
Rituximab for EGPA with severe vasculitic neuropathy: Case report and review of current clinical evidence. :Fanouriakis et al.[2015]   More [Restricted access]
Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis :van Daalen et al.[2016]   More [Restricted access]
B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. :Thiel et al.[2017]   More


Nephrology.
Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.:Jayne et al.[2007]   More
Rituximab for the treatment of Churg Strauss syndrome with renal involvement : Cartin-Ceba et al. [2011]   More

Neuropathy.
The subject of neuropathy and related references is covered in the Neuropathy section.

Ophthalmology.
Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286 patients and review of the literature. : Rothschild et al. [2013]   More [Restricted access]


Otorhinolaryngology.
Ear nose and throat involvement in EGPA : Baldwin, Wolter, Pagnoux. [2015]  More
Ear, nose and throat manifestations of Churg Strauss syndrome. : systematic review. : Bacciu et al. [2006]   More [Restricted access]
Focus on audiologic impairment in EGPA: Data from 17 patients.: long-term follow-up. :Seccia et al.[2016]   More [Restricted access]
Head and Neck Manifestations of EGPA: A Systematic Review :Goldfarb et al.[2016]   More
Nasal polyposis in Churg Strauss Syndrome. : Bacciu et al.[2008]   More [Restricted access]
Otological manifestations of Churg Strauss syndrome. : Ishiyama, Canalis. [2001]   More [Restricted access]

Prognosis.
Clinical features and prognostic factors of Churg Strauss Syndrome : Kim et al.[2014]   More
The impact of current health related quality of life on future health outlook in patients with EGPA : Sokolowska et al. [2013]   More

Pulmonology.
Churg Strauss Syndrome: The spectrum of pulmonary CT findings in 17 patients : Worthy, Muller,Hansell, Flower. [1998]  More
Combined Allergic Bronchopulmonary Aspergillosis and EGPA: Three Cases and a Review of the Literature.: Ishiguro et al.[2016]   More
Diagnostic features and differential diagnosis of Churg Strauss Syndrome in the lung : Anna-Luise A. Katzenstein [2000]  More
Respiratory manifestations of EGPA. :Cottin et al.[2016]   More [Restricted access]
Vasculitis of the upper airways.:Pagnoux, Wolter [2012]   More

Reviews.
Churg Strauss syndrome :Cottin et al.[1999]   More
Churg Strauss Syndrome : Conron, Beynon. [2000]   More
Churg Strauss Syndrome : Gross, Reinhold-Keller. [2002]  More
Churg Strauss Syndrome: evolving concepts :Pagnoux.[2010]   More
EGPA: state of the art : Vaglio, Buzio Zwerina. [2013]  More
EGPA: An overview : Gioffredi et al.[2014]   More
EGPA : Izquierdo-Dominguez et al. [2015]   More
Updates in ANCA-associated vasculitis :Pagnoux.[2016]   More
ANCA-associated vasculitis. : Yates, Watts. [2017]   More
ANCA-associated vasculitis in childhood: recent advances. : Calatroni et al [2017]   More

Vaccination.
Vaccination and autoimmune disease: what is the evidence? : Wraith, Goldman, Lambert [2003]  More
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. :Rubin et al.[2014]   More

Medical papers help.

Important. This is a selection of highly technical medical reading.
Some of the papers listed can only be viewed as a summary or abstract and would need to be purchased if you wish to see the full document.
Having said that, there are some very good papers presenting broad based conclusions which can be viewed in their entirety. A good tip would be to read papers that have been written in the last few years, though there are many older documents to be viewed for those wishing to get a more historical perspective
None of the links are recommendations. Please come to your own conclusions about material presented which is owned by the named authors or the linked site.
Never change your medication regime except under advise of your doctor.

Documents with a might be a good place to start if you are looking for general reading.

Doing your own research. This list is a small selection of materials available and you are encouraged to do your own research. Why not visit 'The Library' for tips on this.

Additions. If you would like something added, clarifying or changing, please ask. You can do this by contacting admin@egpa.info.


Copyright © EGPA.info 2017